This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Wnt Small Molecule (OncoMed/Bayer)
OncoMed Pharmaceuticals, Inc.
Description: OncoMed is developing a small molecule Wnt pathway inhibitor under its collaboration with Bayer Pharma.
OncoMed and Bayer
In June 2010, OncoMed and Bayer announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.
Under the terms of the agreement, Bayer and OncoMed will develop antibodies, protein therapeutics, and small molecules as potential novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. In addition to an upfront cash payment of $40 million, OncoMed is eligible to receive cash payments for product candidates that Bayer options and possible additional payments upon achievement of certain development and commercialization milestones described below. The collaboration could potentially include up to five compounds. The agreement includes potential significant near-term milestone payments from Bayer.
OncoMed will utilize its proprietary human cancer stem cell models to discover and advance antibody and protein therapeutics through Phase I...See full deal structure in Biomedtracker
Partners: Bayer AG
Wnt Small Molecule (OncoMed/Bayer) News
Additional information available to subscribers only: